View ValuationLivzon Pharmaceutical Group 향후 성장Future 기준 점검 2/6Livzon Pharmaceutical Group (는) 각각 연간 10% 및 5.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22.1% 로 예상됩니다.핵심 정보10.0%이익 성장률9.13%EPS 성장률Pharmaceuticals 이익 성장18.2%매출 성장률5.4%향후 자기자본이익률22.12%애널리스트 커버리지Low마지막 업데이트03 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 01Livzon Pharmaceutical Group Inc. to Report First Half, 2026 Results on Aug 22, 2026Livzon Pharmaceutical Group Inc. announced that they will report first half, 2026 results on Aug 22, 2026공고 • May 29+ 1 more updateLivzon Pharmaceutical Group Inc. Approves Dividend for the Year 2025, Payable on or Before 13 July 2026Livzon Pharmaceutical Group Inc. at its AGM held on May 29, 2026, approved to distribute cash dividend of RMB 14.30 (tax inclusive) for every 10 shares to all Shareholders, based on the total number of shares as at the equity registration date for implementation of the 2025 profit distribution plan. The cash dividend will be paid to Shareholders whose names are on the register of the Shareholders of the Company on 17 June 2026. The proposed cash dividend will be denominated in RMB and paid in RMB to A Shareholders and in Hong Kong dollars to H Shareholders. The exchange rate for payment of dividends in Hong Kong dollars shall be based on the middle rate of RMB against Hong Kong dollars announced by the People's Bank of China on the date of the AGM (29 May 2026), which is HKD 1.00 to RMB 0.8703. Accordingly, the cash dividend per 10 H shares of the Company will be approximately HKD 16.43 (tax inclusive). Dividend cheques will be dispatched to H Shareholders entitled to the dividend by ordinary post on or before 13 July 2026 at their own risk. The record date for determining the entitlement of H Shareholders to receive the proposed cash dividend will be 17 June 2026.공고 • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.공고 • Apr 25Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2026Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 6F, No. 38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong China공고 • Mar 31Livzon Pharmaceutical Group Inc. to Report Q1, 2026 Results on Apr 24, 2026Livzon Pharmaceutical Group Inc. announced that they will report Q1, 2026 results on Apr 24, 2026공고 • Mar 25+ 1 more updateLivzon Pharmaceutical Group Inc. Announces Final Dividend for the Year Ended 31 December 2025Livzon Pharmaceutical Group Inc. announced final dividend of RMB 14.3 per 10 share for the year ended 31 December 2025.공고 • Dec 31Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2025 Results on Mar 25, 2026Livzon Pharmaceutical Group Inc. announced that they will report fiscal year 2025 results on Mar 25, 2026공고 • Dec 12Livzon Pharmaceutical Group Inc. Approves the Appointment of Wang Zhiyao as Independent Non-Executive DirectorLivzon Pharmaceutical Group Inc. at its Extraordinary General Meeting held on 10 December 2025 approved the appointment of Ms. Wang Zhiyao as an independent non-executive Director.공고 • Oct 15Livzon Pharmaceutical Group Inc. Announces Resignation of Tian Qiusheng and Wong Kam Wa, Independent Non-Executive DirectorsThe board of directors of Livzon Pharmaceutical Group Inc. (the Company) recently received written resignation letters from Mr. Tian Qiusheng (Mr. Tian) and Mr. Wong Kam Wa (Mr. Wong), both independent non-executive directors. Mr. Tian and Mr. Wong have both served as independent non-executive directors of the Company since 15 October 2019. As at 15 October 2025, they will have served as independent non-executive directors of the Company for six consecutive years. According to the Measures for the Administration of Independent Directors of Listed Companies and the Articles of Association and other relevant regulations, the term of office of an independent director shall not exceed six years. Therefore, Mr. Tian and Mr. Wong submitted written resignation letters to the Board. Mr. Tian applied to resign from the positions of independent non-executive director of the Company's eleventh session of the Board, member of the Audit Committee, Chairman of the Remuneration and Assessment Committee, member of the Nomination Committee and member of the Environmental, Social and Governance Committee. Mr. Wong has applied to resign from his position as a member of the Environmental, Social and Governance Committee.공고 • Sep 30Livzon Pharmaceutical Group Inc. to Report Q3, 2025 Results on Oct 24, 2025Livzon Pharmaceutical Group Inc. announced that they will report Q3, 2025 results on Oct 24, 2025공고 • Jul 02Livzon Pharmaceutical Group Inc. to Report First Half, 2025 Results on Aug 21, 2025Livzon Pharmaceutical Group Inc. announced that they will report first half, 2025 results on Aug 21, 2025공고 • Jun 24Livzon Pharmaceutical Group Inc. Receives Notice of Drug Clinical Trial Approval for YJH-012 injectionLIVzon Pharmaceutical Group Inc. received the Notice of Drug Clinical Trial Approval (Notice No.: 2025LP01629) approved and issued by the National Medical Products Administration, approving YJH-012 injection to carry out clinical trials. Details are as follows: MAIN CONTENTS of the notice of Drug Clinical Trial Approval: Name of drug: YJH-012 injection. Dosage form: Injection. Application: Clinical trial application. Registration classification: Chemical drugs in Category 1. Applicant: Livzon Pharmaceutical Group Inc. Approval conclusion: According to the Pharmaceutical Administration Law of the People's Republic of China (Zhong Hua Ren Min Gong He Guo Yao Pin Guan Li Fa >) and relevant regulations, after review, the application for clinical trial of YJH-012 injection accepted on 14 April 2025 met the relevant requirements of drug registration, and agreed to carry out clinical trials of this product for gout indication. YJH-012 injection is a new type of siRNA drug jointly developed by the Company and Youjia (Hangzhou) Bio-medical Technology Co. Ltd. (Hangzhou) Bio -medical Technology Co. Ltd. ("Hangzhou")Sheng Wu Yi Yao Ke Ji Xian Gong Si"). Different from traditional drugs that inhibit enzyme activity to block uric acid synthesis, YJH-012 injection adopts small interfering RNA (siRNA) technology which is expected to achieve a breakthrough in the mechanism of long-lasting inhibition of uric acid production from the genetic level, with characteristics of long-lasting effect of one injection and better safety potential. The indication of the clinical trials of YJH-012 injections is gout indication. As at the date of this announcement, the accumulated direct investment in research and development expenses of YJH-012jection is about RMB 25.7386 million. MarketET SITUATION of DRUG. According to the website of CDE (Center for Drug Evaluation), as of now, there are no small RNA products with the same indication on the domestic market. Due to the special nature of drug research and development, the process from clinical trials to production and market launch has a long circle and involves many links, which are easy to be affected by unpredictable factors. There are many uncertainties in the progress and results of clinical trials and the future market competition situation of product. The company will timely fulfill its information disclosure obligations according to the progress of research and development, and investors are advised to pay attention to investment risks. Notice is hereby given. Board of Directors of Livzon Pharmaceutical Group Inc. (hereinafter referred to as "the Company") received the Notice of Drug Clinical trial Approval (Notice No.: 25LP01629) approved and issuing by the National Medical Products Administration. Name of drug: YJ H-012 injection. Dosage forms: Injection. Application: clinical trial application. Registration classification: chemical drugs in Category 1. Applicant is the Pharmaceutical Administration Law of the people's Republic of China (ZHong Hua Ren Min Gong HeGuo Yao Pin Guan Li Fa>) and relevant regulations, after reviewed, the application for clinical trial the application for clinical trial ofYJH-012 injection accepted On 14 April 2025 met the relevant needs of drug registration, and agreed To carry out clinical trials of this products for gout indication.공고 • May 30Livzon Pharmaceutical Group Inc. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2024, Payable on 11 July 2025Livzon Pharmaceutical Group Inc. announced ordinary final cash dividend of RMB 11 per 10 share for the year ended December 31, 2024. Date of shareholders' approval is 29 May 2025. Record date is 16 June 2025. Ex-dividend date is 13 June 2025. Payment date is 11 July 2025.공고 • May 22Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement.공고 • Apr 23Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2025Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: conference room, 6th floor of headquarters building, 38 chuangye north road, jinwan district, guangdong province, zhuhai China공고 • Mar 31Livzon Pharmaceutical Group Inc. to Report Q1, 2025 Results on Apr 24, 2025Livzon Pharmaceutical Group Inc. announced that they will report Q1, 2025 results on Apr 24, 2025공고 • Mar 27Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 999.213402 million in fundingLivzon Pharmaceutical Group Inc. announced that it has entered into the 2025 Capital Contribution Agreement that it will issue up to 206,449,050 newly issued ordinary shares of company at an issue price of CNY 4.84 per share for the gross proceeds of up to CNY 999,213,402 on March 26, 2024. Upon completion of the Capital Contribution, the registered capital of company will be increased from CNY 1,095,472,334 to CNY 1,301,921,384, with CNY 866,299,975 to be registered capital attributable to the Company, and the Company’s direct interest in company will increase from 60.23% to 66.54%. The Capital Contribution is expected to be funded by internal resources of the Company. The Capital Contribution shall be paid within 24 months after the completion of change with industrial and commercial registration of company. The transaction has been approved by the board of directors of the company.공고 • Mar 26Livzon Pharmaceutical Group Inc. Announces Final Dividend for the Year Ended 31 December 2024Livzon Pharmaceutical Group Inc. announced Final Dividend of RMB 11 per 10 share for the year ended 31 December 2024.공고 • Jan 02Livzon Pharmaceutical Group Inc. Announces Change of Company Secretary and Authorised RepresentativeOn 31 December 2024, the board of directors of Livzon Pharmaceutical Group Inc. received the written resignation report from Mr. Yang Liang, the company secretary and authorised representative of the Company. Due to the adjustment of work, Mr. Yang applied for resignation as the company secretary of the Company pursuant to Rule 3.28 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and as the authorised representative of the Company pursuant to Rule 3.05 of the Hong Kong Listing Rules. After his resignation, Mr. Yang will continue to serve as the vice president of the Company and the directors of certain of its controlled subsidiaries. The resignation of Mr. Yang as the Company Secretary will not affect the normal operation of the Board and the resignation will take effect from the date of its delivery to the Board. Mr. Yang has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company. During his tenure as the Company Secretary and Authorised Representative, Mr. Yang has acted with due diligence, and the Board would like to express its sincere gratitude to Mr. Yang for his efforts and contributions in the regulated operation, corporate governance and information disclosure of the Company during his tenure. Ms. Liu, born in 1983. Ms Liu obtained bachelor's degree in law from China University of Political Science and Law () in 2006. Since August 2020 to present, Ms. Liu has been the deputy general manager of Zhuhai Livzon Diagnostics Inc. From January 2021 to present, she has been an independent director of Telink Semiconductor (Shanghai) Co. Ltd. Prior to joining the Group, Ms Liu worked in the investment banking department of the securities companies and private equity investment fund, engaging in activities such as domestic and international financing for listed companies, mergers and acquisitions, restructuring, and compliance operation consultations. Ms Liu also holds a certificate of training for board secretaries of listed companies on the Shenzhen Stock Exchange, as well as the qualification of Certified Public Accountant in the PRC, the legal professional qualification in the PRC and the qualification of Chartered Certified Accountant in the United Kingdom.공고 • Dec 31Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2024 Results on Mar 27, 2025Livzon Pharmaceutical Group Inc. announced that they will report fiscal year 2024 results on Mar 27, 2025공고 • Nov 29Livzon Pharmaceutical Group Inc. Announces Election of Lin Nanqi as Non-Executive DirectorLivzon Pharmaceutical Group Inc. announced at the EGM held on November 26, 2024, approved election of Mr. Lin Nanqi as a non-executive director of the 11th session of the board of directors.공고 • Oct 17Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for DrugRecently, Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd., a controlling subsidiary of Livzon Pharmaceutical Group Inc., received the Approval Notice for Supplementary Application for Drug issued by the National Medical Products Administration, stating that Leuprorelin Acetate Microspheres for Injection manufactured by Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. passed the consistency evaluation on quality and efficacy for injectable generic drugs, details of which are announced as follows: Name of the drug: Leuprorelin Acetate Microspheres for Injection. English name/Latin name: Leuprorelin Acetate Microspheres for Injection. Dosage form: injection. Strength: 3.75mg. Registration classification: chemical drug. Original drug approval number: NMPA H20093852. Drug registration standard number: YBH24682024. Application: consistency evaluation on quality and efficacy for generics. Marketing authorization holder and manufacturer: Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. Approval conclusion: Pursuant to the requirements of Drug Administration Law of the People's Republic of China (), Opinions of the State Council on Reform of the System of Evaluation, Review and Approval of Drugs and Medical Devices (Guo Fa [2015] No. 44) (2015 44) and Announcement on Matters Related to Consistency Evaluation on Quality and Efficacy for Generics (No. 100 of 2017) (2017 100), upon review, this drug passed the consistency evaluation on quality and efficacy for injectable generic drugs. Leuprorelin Acetate Microspheres for Injection is a Class B product under the Catalogue of Drugs for National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, which is indicated for (1) endometriosis; (2) hysteromyoma accompanied by menorrhagia, lower abdominal pain, lower back pain and anemia due to the reduction of the size of fibroids and/or the improvement of symptoms; (3) premenopausal breast cancer with estrogen receptor positive; (4) prostate cancer; (5) central precocious puberty. Leuprorelin Acetate Microspheres for Injection is administered subcutaneously once every 4 weeks. It has the characteristics of longer efficacy and lower medication frequency, which can alleviate patients' pain and medication burden, as well as improve tolerance and accessibility of medication. As at the date of the announcement, the accumulated direct R&D expenses for consistency evaluation of Leuprorelin Acetate Microspheres for Injection amounted to approximately RMB 93.1480 million. As at the date of the announcement, a total of two enterprises possessed the production approval for Leuprorelin Acetate prolonged-action sustained-release preparation (excluding patented drug enterprises) in Mainland China, and only Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. has passed the consistency evaluation. Pursuant to the data from IQVIA sampling statistics assessment, domestic terminal sales amount of Leuprorelin Acetate prolonged-action sustained- release preparation in 2023 amounted to approximately RMB 4.660 billion. According to the inquiry, Leuprorelin Acetate Microspheres for Injection of the Company is the world's first GnRH prolonged-action sustained-release preparation approved after completing bioequivalence studies in accordance with the US FDA individual drug guidelines. Passing consistency evaluation is beneficial to further enhancing the market competitiveness of this drug and consolidating dominant position of the Company in the domestic R&D of microsphere preparation. Since medical products are characterized with high technology, high risks, high added value and involve uncertainties as sales of such drugs is susceptible to many unpredictable factors, including national policies and market environment. Investors are advised to exercise caution in decision making and be aware of investment risks.공고 • Oct 14Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as DirectorLivzon Pharmaceutical Group Inc. announced that it has received a written resignation tendered by Mr. Yu Xiong on 14 October 2024. Due to work adjustment, Mr. Yu Xiong has voluntarily resigned from his position of a director of the Company, and will not serve in the Company and its controlled subsidiaries after his resignation. Mr. Yu Xiong's written resignation shall take effect from resignation being delivered to the Board (i.e. 14 October 2024). In accordance with the relevant provisions of the Company Law of the People's Republic of China and the Articles of Association of Livzon Pharmaceutical Group Inc.*, the Company will hold a re-election for the director as soon as possible.공고 • Sep 30Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024Livzon Pharmaceutical Group Inc. announced that they will report Q3, 2024 results on Oct 24, 2024공고 • Jun 29Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024Livzon Pharmaceutical Group Inc. announced that they will report first half, 2024 results on Aug 23, 2024공고 • May 15Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024, at 14:00 China Standard Time. Location: 6F, No. 38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong China공고 • Apr 28Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for InjectionLivzon Pharmaceutical Factory received the approval notice for the ADNA issued by the U.S. Food and Drug Administration (hereinafter referred to as "U.S. FDA"), approving the market launch of Cetrorelix Acetate for Injection developed by the Company in the United States. Cetrorelix Acetsate for Injection is a third-generation gonadotropin-releasing hormone antagonist (GnRH-ant). Cetrorelix AcETate for Injection has the advantages of rapid onset and low incidence of OHSS and adverse events. The Company's Cetrorelix Actate for Injection was approved for market launch in China on 31 December, 2021, and registration applications have been submitted in several overseas countries. As at the disclosure date of this announcement, the accumulated direct research and development costs for Cetrorelix Acitate for Injection amounted to approximately RMB 22.9048 million. As at the disclosure date the disclosure date of this announcement. As at the disclosure date, the accumulated direct research and develop costs for CetrorelIX Acetate for Injection amounted toapproximately RMB 22.9048 billion. As at the disclosure date. As at the disclosure dateof this announcement, Cetrorelix Acmetate for Injection from a total of four companies, including the original research company, (including the original research company, (including the original research company, including the original research company), (including the original research company), (including the original research company), including the original research company, ("including Livzon Group Livzon Pharmaceutical Factory") have been approved for market launch in the U.S., and Cetrorelix Acenen You Xian Gong Si) have been approved for market launch Injection in the U.S.,and Cetrorelix Acotate for In injection from a total of seven companies (including Livzon Group Livzon pharmaceutical Factory) have been approved for market launched in China. Upon enquiry, the global sales amount of CetrorelixAcetate for Injection in 2022 was approximately USD 216.00 million, of which approximately USD 105.00 million was from the U.S. market. Pursuant to the data from IQVIA sampling statistics assessment, the domestic terminal sales amount of Cetro Relix Acetate for In injection in 2023 was approximately RMB241.6436 million.공고 • Mar 30Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024Livzon Pharmaceutical Group Inc. announced that they will report Q1, 2024 results on Apr 24, 2024공고 • Mar 28Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024Livzon Pharmaceutical Group Inc. proposed final dividend of RMB 13.5 per 10 shares for the year ended December 31, 2023. Payment date 05 August 2024.공고 • Dec 29Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024Livzon Pharmaceutical Group Inc. announced that they will report fiscal year 2023 results on Mar 29, 2024공고 • Dec 05Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency UseOn 1 December 2023, Livzon MABPharm Inc. received a letter from the relevant national authorities that, upon the recommendation by the National Health Commission, the National Medical Products Administration (the "NMPA") conducted the expert review and approved the inclusion of the Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (CHO Cell) (the "Product"), developed and produced by Livzon MAB, for emergency use. The Product is the second SARS-CoV-2 vaccine product developed by the Company to be included in the national emergency use, following the Recombinant SARS -CoV-2 Fusion Protein Vaccine (Zhong Zu Xin Xing Guan Zhuang Bing Du Rong He Dan Bai Yi Miao) ("LIKANG V-01"). Clinical trials for the Product have been conducted according to the clinical protocol approved by the NMPA. Up to now, the enrolment of all subjects (a total of 4,750 subjects, including 2,002 elderly subjects) has been completed, successfully achieving the primary endpoints predefined for the clinical study. The clinical trial results reveal a rapid elevation in neutralizing antibody titers on Day 7 after the vaccination of the Product, with peak levels reached on Day 14 and a comparable level sustained on Day 28. The neutralizing antibody titer against the XBB.1.9.1 live virus is 407.9, demonstrating a significant superiority compared to the prototype vaccine V-01. Moreover, the neutralizing antibody titers in the elderly group are equivalent to those observed in the adult group. Meanwhile, the Product demonstrates a broad-spectrum neutralizing effect against multiple prevalent variants, such as EG.5.1, XBB.1.9, XBB.1.16, and XBB.1.5, highlighting its robust protective effects against the predominant strains. The Product has promising safety profile, with adverse events predominantly characterized as mild and commonly observed. The overall incidence is low, and the incidence of adverse events in the elderly group is lower than that in the adult group. No new risks have been identified in the Product when compared to the prototype vaccine V the01.공고 • Nov 01Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.Livzon Pharmaceutical Group Inc. (SZSE:000513) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its class A shares. The program will be valid for a period of 12 months.공고 • Aug 25Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for InjectionLivzon Pharmaceutical Group Inc. and its controlling subsidiary, Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. received the "Notice of Acceptance" (acceptance No.: CXHS2300072) issued by the National Medical Products Administration (the "NMPA"), which accepted the application for the registration and marketing authorization of Triptorelin Acetate Microspheres for Injection (Zhu She Yong Cu Suan Qu Pu Rui Lin Wei Qiu) against endometriosis. Common name of drug: Triptorelin Acetate Microspheres for Injection; English Name: Triptorelin Acetate Microspheres for Injection; Dosage form: injection; Strength: 3.75mg (based on C64H82N18O13); Application: registration and marketing authorization for domestically manufactured drug; Registration classification: Class 2.4 chemical drug; Review conclusion of the notice of acceptance: It has been determined after review that the application was accepted in accordance with the provision of Article 32 of the "Administrative Licensing Law of the PRC. Triptorelin Acetate Microspheres for Injection is a high-end long-acting microsphere preparation independently developed by the Company, and was approved for market launch in May 2023. It is applicable to "prostate cancer patients who need androgen deprivation therapy". For details, please refer to the ANNOUNCEMENT ON THE RECEIPT OF REGISTRATION APPROVAL FOR TRIPTORELIN ACETATE MICROSPHERES FOR INJECTION (Announcement No.: 2023-037) issued by the Company on 11 May 2023. The indication accepted this time is endometriosis. The drug is a gonadotropin-releasing hormone agonist for an intramuscular injection every month. Compared with ordinary triptorelin acetate injection, it has the characteristics of longer efficacy and reduced medication frequency, which can alleviate patients' pain and medication burden, as well as improve tolerance and accessibility of medication. As at the date of this announcement, the accumulated direct investment expenses in research and development of Triptorelin Acetate Microspheres for Injection is approximately RMB 116.5682 million. RISK WARNING: According to the requirements of national laws and regulations related to drug registration, the above- mentioned drug will be transferred to the CDE for review and approval upon acceptance of the NMPA registration application, and the completion time and approval results are uncertain. The new indication can greatly expand the application scope of the drug, solve clinical needs, and further improve the market competitiveness of the drug. The Company will fulfill its information disclosure obligations in a timely manner in accordance with the progress of research and development, and investors are kindly advised to make prudent decisions and pay attention to investment risks.공고 • Jul 01Livzon Pharmaceutical Group Inc. Announces Board AppointmentsLivzon Pharmaceutical Group Inc. announced that the first meeting of the 11th session of the board of directors of the company appointed Mr. Zhu Baoguo as the chairman of the 11th session of the board of directors of the company, and appointed Mr. Tao Desheng and Mr. Xu Guoxiang as the vice chairman of the 11th session of the board of directors of the company on 30 June 2023. On 30 June 2023, the first meeting of the 11th session of the supervisory committee of the company appointed Mr. Wang Maolin as the chief supervisor (the Chief Supervisor) of the 11th session of the supervisory committee of the company. The tenures of the Chairman, Vice chairman and Chief Supervisor will commence on 30 June 2023, and end upon the expiry of the three-year tenure of the 11th session of the board of directors and the 11th session of the supervisory committee.공고 • Jun 29+ 1 more updateLivzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023Livzon Pharmaceutical Group Inc. announced the final cash dividend (A shares) (tax included) for 2022 of CNY 16.00000000 per 10 shares. The dividend will be payable on 04 July 2023 with Record date of 03 July 2023 and Ex-date of 04 July 2023.공고 • Jun 22Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023Livzon Pharmaceutical Group Inc. approved final cash dividend of RMB 1.6 per share for the year ended 31 December 2022, payable on 31 July 2023. Record date is 05 July 2023. Ex-dividend date is 04 July 2023. Date of shareholders' approval is 21 June 2023.공고 • Jan 20Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection AtvtiaLivzon Pharmaceutical Group Inc. was informed from the website of the National Medical Products Administration that the application for drug marketing authorisation submitted by Livzon MABPharm Inc., a controlling subsidiary of the Company, for the Tocilizumab Injection Atvtia was approved. The Company hereby announced the relevant details: Common name of the drug: Tocilizumab Injection; Trade name: Atvtia; Dosage form: Injection; Specification: 80 mg/4 ml; Application: Drug registration (domestic production); Category of registration: Therapeutic biological products; Applicant: Livzon MABPharm Inc. R&D OF THE DRUG AND RELEVANT DETAILS: Atvtia is a Tocilizumab injection developed on the basis of biosimilars with Tocilizumab (Actemra) of Roche as the reference drug. The application for registration for marketing was accepted in December 2021 (acceptance number: CXSS2101056 Guo). The product is indicated for the treatment of rheumatoid arthritis. Atvtia is a recombinant humanised monoclonal antibody targeting interleukin-6 receptor (IL-6R) that specifically binds to soluble and membrane-binding IL-6 receptor (sIL-6R and mIL-6R) and inhibits signaling mediated by sIL-6R or mIL-6R. Through comprehensive quality similarity study, preclinical study, clinical pharmacokinetics comparison study, and clinical efficacy and safety comparison study, Atvtia has been well demonstrated to be highly similar in terms of quality, safety and efficacy to Actemra, the reference drug. After approval for marketing, Atvtia could further benefit autoimmune patients in China. At present, Tocilizumab Injection has been included in the Diagnosis and Treatment Plan for Novel Coronavirus Infection (Tenth Edition for Trial Implementation) and the Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Fourth Edition for Trial Implementation). It can be given a tryout for severe cases with significant increase in level of IL-6 in laboratory testing.이익 및 매출 성장 예측OTCPK:LVZP.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202813,4822,571N/AN/A312/31/202712,8672,307N/A2,396412/31/202611,8812,048N/A3,10223/31/202611,7111,9632,7133,238N/A12/31/202512,0202,0232,5713,145N/A9/30/202511,8472,1422,5363,196N/A6/30/202511,8022,1712,4493,136N/A3/31/202511,7502,0902,2252,779N/A12/31/202411,8122,0612,4092,979N/A9/30/202411,8572,0252,6733,344N/A6/30/202412,0221,9902,8603,552N/A3/31/202412,2601,9803,0443,873N/A12/31/202312,4301,9542,4283,249N/A9/30/202312,7962,0042,4333,137N/A6/30/202313,0172,0261,8272,574N/A3/31/202312,5641,9381,4772,362N/A12/31/202212,6301,9091,8332,773N/A9/30/202212,1831,8301,1522,445N/A6/30/202212,1311,7311,2362,654N/A3/31/202212,1931,8098332,098N/A1/1/202212,0641,7765931,902N/A9/30/202111,9641,7469051,948N/A6/30/202111,6611,7731,0361,962N/A3/31/202111,3651,8351,5072,313N/A1/1/202110,5201,7151,5142,161N/A9/30/202010,0151,6851,3421,857N/A6/30/20209,5411,5691,2721,682N/A3/31/20209,2821,3091,2361,649N/A1/1/20209,3851,303N/A1,767N/A9/30/20199,3141,182N/A2,069N/A6/30/20199,2351,188N/A2,244N/A3/31/20199,0991,128N/A1,540N/A12/31/20188,8611,082N/A1,268N/A9/30/20188,8511,123N/A1,015N/A6/30/20188,8214,558N/A850N/A3/31/20188,7744,501N/A1,266N/A1/1/20188,5314,429N/A1,316N/A9/30/20178,4504,416N/A1,324N/A6/30/20178,142879N/A1,419N/A3/31/20178,032829N/A1,399N/A12/31/20167,652784N/A1,279N/A9/30/20167,458742N/A1,240N/A6/30/20167,289691N/A1,002N/A3/31/20166,813670N/A990N/A12/31/20156,621623N/A928N/A9/30/20156,311588N/A894N/A6/30/20156,031566N/A748N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: LVZP.F 의 연간 예상 수익 증가율(10%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: LVZP.F 의 연간 수익(10%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: LVZP.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: LVZP.F 의 수익(연간 5.4%)이 US 시장(연간 12.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: LVZP.F 의 수익(연간 5.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: LVZP.F의 자본 수익률은 3년 후 22.1%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/23 02:17종가2026/03/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Livzon Pharmaceutical Group Inc.는 18명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Helena QiuCCB International Securities LimitedYanyin ZhuChina International Capital Corporation LimitedYou You LiuChina Stock Investment Research Co. Ltd. (DeepValue.online)15명의 분석가 더 보기
공고 • Jul 01Livzon Pharmaceutical Group Inc. to Report First Half, 2026 Results on Aug 22, 2026Livzon Pharmaceutical Group Inc. announced that they will report first half, 2026 results on Aug 22, 2026
공고 • May 29+ 1 more updateLivzon Pharmaceutical Group Inc. Approves Dividend for the Year 2025, Payable on or Before 13 July 2026Livzon Pharmaceutical Group Inc. at its AGM held on May 29, 2026, approved to distribute cash dividend of RMB 14.30 (tax inclusive) for every 10 shares to all Shareholders, based on the total number of shares as at the equity registration date for implementation of the 2025 profit distribution plan. The cash dividend will be paid to Shareholders whose names are on the register of the Shareholders of the Company on 17 June 2026. The proposed cash dividend will be denominated in RMB and paid in RMB to A Shareholders and in Hong Kong dollars to H Shareholders. The exchange rate for payment of dividends in Hong Kong dollars shall be based on the middle rate of RMB against Hong Kong dollars announced by the People's Bank of China on the date of the AGM (29 May 2026), which is HKD 1.00 to RMB 0.8703. Accordingly, the cash dividend per 10 H shares of the Company will be approximately HKD 16.43 (tax inclusive). Dividend cheques will be dispatched to H Shareholders entitled to the dividend by ordinary post on or before 13 July 2026 at their own risk. The record date for determining the entitlement of H Shareholders to receive the proposed cash dividend will be 17 June 2026.
공고 • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.
공고 • Apr 25Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2026Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 6F, No. 38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong China
공고 • Mar 31Livzon Pharmaceutical Group Inc. to Report Q1, 2026 Results on Apr 24, 2026Livzon Pharmaceutical Group Inc. announced that they will report Q1, 2026 results on Apr 24, 2026
공고 • Mar 25+ 1 more updateLivzon Pharmaceutical Group Inc. Announces Final Dividend for the Year Ended 31 December 2025Livzon Pharmaceutical Group Inc. announced final dividend of RMB 14.3 per 10 share for the year ended 31 December 2025.
공고 • Dec 31Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2025 Results on Mar 25, 2026Livzon Pharmaceutical Group Inc. announced that they will report fiscal year 2025 results on Mar 25, 2026
공고 • Dec 12Livzon Pharmaceutical Group Inc. Approves the Appointment of Wang Zhiyao as Independent Non-Executive DirectorLivzon Pharmaceutical Group Inc. at its Extraordinary General Meeting held on 10 December 2025 approved the appointment of Ms. Wang Zhiyao as an independent non-executive Director.
공고 • Oct 15Livzon Pharmaceutical Group Inc. Announces Resignation of Tian Qiusheng and Wong Kam Wa, Independent Non-Executive DirectorsThe board of directors of Livzon Pharmaceutical Group Inc. (the Company) recently received written resignation letters from Mr. Tian Qiusheng (Mr. Tian) and Mr. Wong Kam Wa (Mr. Wong), both independent non-executive directors. Mr. Tian and Mr. Wong have both served as independent non-executive directors of the Company since 15 October 2019. As at 15 October 2025, they will have served as independent non-executive directors of the Company for six consecutive years. According to the Measures for the Administration of Independent Directors of Listed Companies and the Articles of Association and other relevant regulations, the term of office of an independent director shall not exceed six years. Therefore, Mr. Tian and Mr. Wong submitted written resignation letters to the Board. Mr. Tian applied to resign from the positions of independent non-executive director of the Company's eleventh session of the Board, member of the Audit Committee, Chairman of the Remuneration and Assessment Committee, member of the Nomination Committee and member of the Environmental, Social and Governance Committee. Mr. Wong has applied to resign from his position as a member of the Environmental, Social and Governance Committee.
공고 • Sep 30Livzon Pharmaceutical Group Inc. to Report Q3, 2025 Results on Oct 24, 2025Livzon Pharmaceutical Group Inc. announced that they will report Q3, 2025 results on Oct 24, 2025
공고 • Jul 02Livzon Pharmaceutical Group Inc. to Report First Half, 2025 Results on Aug 21, 2025Livzon Pharmaceutical Group Inc. announced that they will report first half, 2025 results on Aug 21, 2025
공고 • Jun 24Livzon Pharmaceutical Group Inc. Receives Notice of Drug Clinical Trial Approval for YJH-012 injectionLIVzon Pharmaceutical Group Inc. received the Notice of Drug Clinical Trial Approval (Notice No.: 2025LP01629) approved and issued by the National Medical Products Administration, approving YJH-012 injection to carry out clinical trials. Details are as follows: MAIN CONTENTS of the notice of Drug Clinical Trial Approval: Name of drug: YJH-012 injection. Dosage form: Injection. Application: Clinical trial application. Registration classification: Chemical drugs in Category 1. Applicant: Livzon Pharmaceutical Group Inc. Approval conclusion: According to the Pharmaceutical Administration Law of the People's Republic of China (Zhong Hua Ren Min Gong He Guo Yao Pin Guan Li Fa >) and relevant regulations, after review, the application for clinical trial of YJH-012 injection accepted on 14 April 2025 met the relevant requirements of drug registration, and agreed to carry out clinical trials of this product for gout indication. YJH-012 injection is a new type of siRNA drug jointly developed by the Company and Youjia (Hangzhou) Bio-medical Technology Co. Ltd. (Hangzhou) Bio -medical Technology Co. Ltd. ("Hangzhou")Sheng Wu Yi Yao Ke Ji Xian Gong Si"). Different from traditional drugs that inhibit enzyme activity to block uric acid synthesis, YJH-012 injection adopts small interfering RNA (siRNA) technology which is expected to achieve a breakthrough in the mechanism of long-lasting inhibition of uric acid production from the genetic level, with characteristics of long-lasting effect of one injection and better safety potential. The indication of the clinical trials of YJH-012 injections is gout indication. As at the date of this announcement, the accumulated direct investment in research and development expenses of YJH-012jection is about RMB 25.7386 million. MarketET SITUATION of DRUG. According to the website of CDE (Center for Drug Evaluation), as of now, there are no small RNA products with the same indication on the domestic market. Due to the special nature of drug research and development, the process from clinical trials to production and market launch has a long circle and involves many links, which are easy to be affected by unpredictable factors. There are many uncertainties in the progress and results of clinical trials and the future market competition situation of product. The company will timely fulfill its information disclosure obligations according to the progress of research and development, and investors are advised to pay attention to investment risks. Notice is hereby given. Board of Directors of Livzon Pharmaceutical Group Inc. (hereinafter referred to as "the Company") received the Notice of Drug Clinical trial Approval (Notice No.: 25LP01629) approved and issuing by the National Medical Products Administration. Name of drug: YJ H-012 injection. Dosage forms: Injection. Application: clinical trial application. Registration classification: chemical drugs in Category 1. Applicant is the Pharmaceutical Administration Law of the people's Republic of China (ZHong Hua Ren Min Gong HeGuo Yao Pin Guan Li Fa>) and relevant regulations, after reviewed, the application for clinical trial the application for clinical trial ofYJH-012 injection accepted On 14 April 2025 met the relevant needs of drug registration, and agreed To carry out clinical trials of this products for gout indication.
공고 • May 30Livzon Pharmaceutical Group Inc. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2024, Payable on 11 July 2025Livzon Pharmaceutical Group Inc. announced ordinary final cash dividend of RMB 11 per 10 share for the year ended December 31, 2024. Date of shareholders' approval is 29 May 2025. Record date is 16 June 2025. Ex-dividend date is 13 June 2025. Payment date is 11 July 2025.
공고 • May 22Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement.
공고 • Apr 23Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2025Livzon Pharmaceutical Group Inc., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: conference room, 6th floor of headquarters building, 38 chuangye north road, jinwan district, guangdong province, zhuhai China
공고 • Mar 31Livzon Pharmaceutical Group Inc. to Report Q1, 2025 Results on Apr 24, 2025Livzon Pharmaceutical Group Inc. announced that they will report Q1, 2025 results on Apr 24, 2025
공고 • Mar 27Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 999.213402 million in fundingLivzon Pharmaceutical Group Inc. announced that it has entered into the 2025 Capital Contribution Agreement that it will issue up to 206,449,050 newly issued ordinary shares of company at an issue price of CNY 4.84 per share for the gross proceeds of up to CNY 999,213,402 on March 26, 2024. Upon completion of the Capital Contribution, the registered capital of company will be increased from CNY 1,095,472,334 to CNY 1,301,921,384, with CNY 866,299,975 to be registered capital attributable to the Company, and the Company’s direct interest in company will increase from 60.23% to 66.54%. The Capital Contribution is expected to be funded by internal resources of the Company. The Capital Contribution shall be paid within 24 months after the completion of change with industrial and commercial registration of company. The transaction has been approved by the board of directors of the company.
공고 • Mar 26Livzon Pharmaceutical Group Inc. Announces Final Dividend for the Year Ended 31 December 2024Livzon Pharmaceutical Group Inc. announced Final Dividend of RMB 11 per 10 share for the year ended 31 December 2024.
공고 • Jan 02Livzon Pharmaceutical Group Inc. Announces Change of Company Secretary and Authorised RepresentativeOn 31 December 2024, the board of directors of Livzon Pharmaceutical Group Inc. received the written resignation report from Mr. Yang Liang, the company secretary and authorised representative of the Company. Due to the adjustment of work, Mr. Yang applied for resignation as the company secretary of the Company pursuant to Rule 3.28 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and as the authorised representative of the Company pursuant to Rule 3.05 of the Hong Kong Listing Rules. After his resignation, Mr. Yang will continue to serve as the vice president of the Company and the directors of certain of its controlled subsidiaries. The resignation of Mr. Yang as the Company Secretary will not affect the normal operation of the Board and the resignation will take effect from the date of its delivery to the Board. Mr. Yang has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company. During his tenure as the Company Secretary and Authorised Representative, Mr. Yang has acted with due diligence, and the Board would like to express its sincere gratitude to Mr. Yang for his efforts and contributions in the regulated operation, corporate governance and information disclosure of the Company during his tenure. Ms. Liu, born in 1983. Ms Liu obtained bachelor's degree in law from China University of Political Science and Law () in 2006. Since August 2020 to present, Ms. Liu has been the deputy general manager of Zhuhai Livzon Diagnostics Inc. From January 2021 to present, she has been an independent director of Telink Semiconductor (Shanghai) Co. Ltd. Prior to joining the Group, Ms Liu worked in the investment banking department of the securities companies and private equity investment fund, engaging in activities such as domestic and international financing for listed companies, mergers and acquisitions, restructuring, and compliance operation consultations. Ms Liu also holds a certificate of training for board secretaries of listed companies on the Shenzhen Stock Exchange, as well as the qualification of Certified Public Accountant in the PRC, the legal professional qualification in the PRC and the qualification of Chartered Certified Accountant in the United Kingdom.
공고 • Dec 31Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2024 Results on Mar 27, 2025Livzon Pharmaceutical Group Inc. announced that they will report fiscal year 2024 results on Mar 27, 2025
공고 • Nov 29Livzon Pharmaceutical Group Inc. Announces Election of Lin Nanqi as Non-Executive DirectorLivzon Pharmaceutical Group Inc. announced at the EGM held on November 26, 2024, approved election of Mr. Lin Nanqi as a non-executive director of the 11th session of the board of directors.
공고 • Oct 17Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for DrugRecently, Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd., a controlling subsidiary of Livzon Pharmaceutical Group Inc., received the Approval Notice for Supplementary Application for Drug issued by the National Medical Products Administration, stating that Leuprorelin Acetate Microspheres for Injection manufactured by Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. passed the consistency evaluation on quality and efficacy for injectable generic drugs, details of which are announced as follows: Name of the drug: Leuprorelin Acetate Microspheres for Injection. English name/Latin name: Leuprorelin Acetate Microspheres for Injection. Dosage form: injection. Strength: 3.75mg. Registration classification: chemical drug. Original drug approval number: NMPA H20093852. Drug registration standard number: YBH24682024. Application: consistency evaluation on quality and efficacy for generics. Marketing authorization holder and manufacturer: Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. Approval conclusion: Pursuant to the requirements of Drug Administration Law of the People's Republic of China (), Opinions of the State Council on Reform of the System of Evaluation, Review and Approval of Drugs and Medical Devices (Guo Fa [2015] No. 44) (2015 44) and Announcement on Matters Related to Consistency Evaluation on Quality and Efficacy for Generics (No. 100 of 2017) (2017 100), upon review, this drug passed the consistency evaluation on quality and efficacy for injectable generic drugs. Leuprorelin Acetate Microspheres for Injection is a Class B product under the Catalogue of Drugs for National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, which is indicated for (1) endometriosis; (2) hysteromyoma accompanied by menorrhagia, lower abdominal pain, lower back pain and anemia due to the reduction of the size of fibroids and/or the improvement of symptoms; (3) premenopausal breast cancer with estrogen receptor positive; (4) prostate cancer; (5) central precocious puberty. Leuprorelin Acetate Microspheres for Injection is administered subcutaneously once every 4 weeks. It has the characteristics of longer efficacy and lower medication frequency, which can alleviate patients' pain and medication burden, as well as improve tolerance and accessibility of medication. As at the date of the announcement, the accumulated direct R&D expenses for consistency evaluation of Leuprorelin Acetate Microspheres for Injection amounted to approximately RMB 93.1480 million. As at the date of the announcement, a total of two enterprises possessed the production approval for Leuprorelin Acetate prolonged-action sustained-release preparation (excluding patented drug enterprises) in Mainland China, and only Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. has passed the consistency evaluation. Pursuant to the data from IQVIA sampling statistics assessment, domestic terminal sales amount of Leuprorelin Acetate prolonged-action sustained- release preparation in 2023 amounted to approximately RMB 4.660 billion. According to the inquiry, Leuprorelin Acetate Microspheres for Injection of the Company is the world's first GnRH prolonged-action sustained-release preparation approved after completing bioequivalence studies in accordance with the US FDA individual drug guidelines. Passing consistency evaluation is beneficial to further enhancing the market competitiveness of this drug and consolidating dominant position of the Company in the domestic R&D of microsphere preparation. Since medical products are characterized with high technology, high risks, high added value and involve uncertainties as sales of such drugs is susceptible to many unpredictable factors, including national policies and market environment. Investors are advised to exercise caution in decision making and be aware of investment risks.
공고 • Oct 14Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as DirectorLivzon Pharmaceutical Group Inc. announced that it has received a written resignation tendered by Mr. Yu Xiong on 14 October 2024. Due to work adjustment, Mr. Yu Xiong has voluntarily resigned from his position of a director of the Company, and will not serve in the Company and its controlled subsidiaries after his resignation. Mr. Yu Xiong's written resignation shall take effect from resignation being delivered to the Board (i.e. 14 October 2024). In accordance with the relevant provisions of the Company Law of the People's Republic of China and the Articles of Association of Livzon Pharmaceutical Group Inc.*, the Company will hold a re-election for the director as soon as possible.
공고 • Sep 30Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024Livzon Pharmaceutical Group Inc. announced that they will report Q3, 2024 results on Oct 24, 2024
공고 • Jun 29Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024Livzon Pharmaceutical Group Inc. announced that they will report first half, 2024 results on Aug 23, 2024
공고 • May 15Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024, at 14:00 China Standard Time. Location: 6F, No. 38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong China
공고 • Apr 28Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for InjectionLivzon Pharmaceutical Factory received the approval notice for the ADNA issued by the U.S. Food and Drug Administration (hereinafter referred to as "U.S. FDA"), approving the market launch of Cetrorelix Acetate for Injection developed by the Company in the United States. Cetrorelix Acetsate for Injection is a third-generation gonadotropin-releasing hormone antagonist (GnRH-ant). Cetrorelix AcETate for Injection has the advantages of rapid onset and low incidence of OHSS and adverse events. The Company's Cetrorelix Actate for Injection was approved for market launch in China on 31 December, 2021, and registration applications have been submitted in several overseas countries. As at the disclosure date of this announcement, the accumulated direct research and development costs for Cetrorelix Acitate for Injection amounted to approximately RMB 22.9048 million. As at the disclosure date the disclosure date of this announcement. As at the disclosure date, the accumulated direct research and develop costs for CetrorelIX Acetate for Injection amounted toapproximately RMB 22.9048 billion. As at the disclosure date. As at the disclosure dateof this announcement, Cetrorelix Acmetate for Injection from a total of four companies, including the original research company, (including the original research company, (including the original research company, including the original research company), (including the original research company), (including the original research company), including the original research company, ("including Livzon Group Livzon Pharmaceutical Factory") have been approved for market launch in the U.S., and Cetrorelix Acenen You Xian Gong Si) have been approved for market launch Injection in the U.S.,and Cetrorelix Acotate for In injection from a total of seven companies (including Livzon Group Livzon pharmaceutical Factory) have been approved for market launched in China. Upon enquiry, the global sales amount of CetrorelixAcetate for Injection in 2022 was approximately USD 216.00 million, of which approximately USD 105.00 million was from the U.S. market. Pursuant to the data from IQVIA sampling statistics assessment, the domestic terminal sales amount of Cetro Relix Acetate for In injection in 2023 was approximately RMB241.6436 million.
공고 • Mar 30Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024Livzon Pharmaceutical Group Inc. announced that they will report Q1, 2024 results on Apr 24, 2024
공고 • Mar 28Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024Livzon Pharmaceutical Group Inc. proposed final dividend of RMB 13.5 per 10 shares for the year ended December 31, 2023. Payment date 05 August 2024.
공고 • Dec 29Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024Livzon Pharmaceutical Group Inc. announced that they will report fiscal year 2023 results on Mar 29, 2024
공고 • Dec 05Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency UseOn 1 December 2023, Livzon MABPharm Inc. received a letter from the relevant national authorities that, upon the recommendation by the National Health Commission, the National Medical Products Administration (the "NMPA") conducted the expert review and approved the inclusion of the Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (CHO Cell) (the "Product"), developed and produced by Livzon MAB, for emergency use. The Product is the second SARS-CoV-2 vaccine product developed by the Company to be included in the national emergency use, following the Recombinant SARS -CoV-2 Fusion Protein Vaccine (Zhong Zu Xin Xing Guan Zhuang Bing Du Rong He Dan Bai Yi Miao) ("LIKANG V-01"). Clinical trials for the Product have been conducted according to the clinical protocol approved by the NMPA. Up to now, the enrolment of all subjects (a total of 4,750 subjects, including 2,002 elderly subjects) has been completed, successfully achieving the primary endpoints predefined for the clinical study. The clinical trial results reveal a rapid elevation in neutralizing antibody titers on Day 7 after the vaccination of the Product, with peak levels reached on Day 14 and a comparable level sustained on Day 28. The neutralizing antibody titer against the XBB.1.9.1 live virus is 407.9, demonstrating a significant superiority compared to the prototype vaccine V-01. Moreover, the neutralizing antibody titers in the elderly group are equivalent to those observed in the adult group. Meanwhile, the Product demonstrates a broad-spectrum neutralizing effect against multiple prevalent variants, such as EG.5.1, XBB.1.9, XBB.1.16, and XBB.1.5, highlighting its robust protective effects against the predominant strains. The Product has promising safety profile, with adverse events predominantly characterized as mild and commonly observed. The overall incidence is low, and the incidence of adverse events in the elderly group is lower than that in the adult group. No new risks have been identified in the Product when compared to the prototype vaccine V the01.
공고 • Nov 01Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.Livzon Pharmaceutical Group Inc. (SZSE:000513) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its class A shares. The program will be valid for a period of 12 months.
공고 • Aug 25Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for InjectionLivzon Pharmaceutical Group Inc. and its controlling subsidiary, Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. received the "Notice of Acceptance" (acceptance No.: CXHS2300072) issued by the National Medical Products Administration (the "NMPA"), which accepted the application for the registration and marketing authorization of Triptorelin Acetate Microspheres for Injection (Zhu She Yong Cu Suan Qu Pu Rui Lin Wei Qiu) against endometriosis. Common name of drug: Triptorelin Acetate Microspheres for Injection; English Name: Triptorelin Acetate Microspheres for Injection; Dosage form: injection; Strength: 3.75mg (based on C64H82N18O13); Application: registration and marketing authorization for domestically manufactured drug; Registration classification: Class 2.4 chemical drug; Review conclusion of the notice of acceptance: It has been determined after review that the application was accepted in accordance with the provision of Article 32 of the "Administrative Licensing Law of the PRC. Triptorelin Acetate Microspheres for Injection is a high-end long-acting microsphere preparation independently developed by the Company, and was approved for market launch in May 2023. It is applicable to "prostate cancer patients who need androgen deprivation therapy". For details, please refer to the ANNOUNCEMENT ON THE RECEIPT OF REGISTRATION APPROVAL FOR TRIPTORELIN ACETATE MICROSPHERES FOR INJECTION (Announcement No.: 2023-037) issued by the Company on 11 May 2023. The indication accepted this time is endometriosis. The drug is a gonadotropin-releasing hormone agonist for an intramuscular injection every month. Compared with ordinary triptorelin acetate injection, it has the characteristics of longer efficacy and reduced medication frequency, which can alleviate patients' pain and medication burden, as well as improve tolerance and accessibility of medication. As at the date of this announcement, the accumulated direct investment expenses in research and development of Triptorelin Acetate Microspheres for Injection is approximately RMB 116.5682 million. RISK WARNING: According to the requirements of national laws and regulations related to drug registration, the above- mentioned drug will be transferred to the CDE for review and approval upon acceptance of the NMPA registration application, and the completion time and approval results are uncertain. The new indication can greatly expand the application scope of the drug, solve clinical needs, and further improve the market competitiveness of the drug. The Company will fulfill its information disclosure obligations in a timely manner in accordance with the progress of research and development, and investors are kindly advised to make prudent decisions and pay attention to investment risks.
공고 • Jul 01Livzon Pharmaceutical Group Inc. Announces Board AppointmentsLivzon Pharmaceutical Group Inc. announced that the first meeting of the 11th session of the board of directors of the company appointed Mr. Zhu Baoguo as the chairman of the 11th session of the board of directors of the company, and appointed Mr. Tao Desheng and Mr. Xu Guoxiang as the vice chairman of the 11th session of the board of directors of the company on 30 June 2023. On 30 June 2023, the first meeting of the 11th session of the supervisory committee of the company appointed Mr. Wang Maolin as the chief supervisor (the Chief Supervisor) of the 11th session of the supervisory committee of the company. The tenures of the Chairman, Vice chairman and Chief Supervisor will commence on 30 June 2023, and end upon the expiry of the three-year tenure of the 11th session of the board of directors and the 11th session of the supervisory committee.
공고 • Jun 29+ 1 more updateLivzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023Livzon Pharmaceutical Group Inc. announced the final cash dividend (A shares) (tax included) for 2022 of CNY 16.00000000 per 10 shares. The dividend will be payable on 04 July 2023 with Record date of 03 July 2023 and Ex-date of 04 July 2023.
공고 • Jun 22Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023Livzon Pharmaceutical Group Inc. approved final cash dividend of RMB 1.6 per share for the year ended 31 December 2022, payable on 31 July 2023. Record date is 05 July 2023. Ex-dividend date is 04 July 2023. Date of shareholders' approval is 21 June 2023.
공고 • Jan 20Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection AtvtiaLivzon Pharmaceutical Group Inc. was informed from the website of the National Medical Products Administration that the application for drug marketing authorisation submitted by Livzon MABPharm Inc., a controlling subsidiary of the Company, for the Tocilizumab Injection Atvtia was approved. The Company hereby announced the relevant details: Common name of the drug: Tocilizumab Injection; Trade name: Atvtia; Dosage form: Injection; Specification: 80 mg/4 ml; Application: Drug registration (domestic production); Category of registration: Therapeutic biological products; Applicant: Livzon MABPharm Inc. R&D OF THE DRUG AND RELEVANT DETAILS: Atvtia is a Tocilizumab injection developed on the basis of biosimilars with Tocilizumab (Actemra) of Roche as the reference drug. The application for registration for marketing was accepted in December 2021 (acceptance number: CXSS2101056 Guo). The product is indicated for the treatment of rheumatoid arthritis. Atvtia is a recombinant humanised monoclonal antibody targeting interleukin-6 receptor (IL-6R) that specifically binds to soluble and membrane-binding IL-6 receptor (sIL-6R and mIL-6R) and inhibits signaling mediated by sIL-6R or mIL-6R. Through comprehensive quality similarity study, preclinical study, clinical pharmacokinetics comparison study, and clinical efficacy and safety comparison study, Atvtia has been well demonstrated to be highly similar in terms of quality, safety and efficacy to Actemra, the reference drug. After approval for marketing, Atvtia could further benefit autoimmune patients in China. At present, Tocilizumab Injection has been included in the Diagnosis and Treatment Plan for Novel Coronavirus Infection (Tenth Edition for Trial Implementation) and the Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Fourth Edition for Trial Implementation). It can be given a tryout for severe cases with significant increase in level of IL-6 in laboratory testing.